AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (3 x 50,000 IU/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadinum (3 x 4 mg/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: DE‐NOL (3 x 5 mL/day)
Number of subjects: 441
Study 7881027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisacid (Al‐Mg‐hydroxycarbonicum; in different doses)
Number of subjects: 441
Study 3355243 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 15
Study 3355243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3355243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.21 ppm)
Number of subjects: 15
Study 3355243 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 15
Study 29740980 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping planning intervention
Number of subjects: 177
Study 29740980 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (repetition of interventions from first intervention phase)
Number of subjects: 177
Study 28449657 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment
Number of subjects: 0
Study 25646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 29
Study 22537517 — intervention group
Group type: EXPERIMENTAL
Intervention: u‐HA/PLLA plate
Number of subjects: 60
Study 22537517 — intervention group
Group type: COMPARATOR
Intervention: PLLA plate
Number of subjects: 60
Study 22537517 — intervention group
Group type: COMPARATOR
Intervention: Titanium plate
Number of subjects: 60
Study 20595145 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 μg, 2 × 2 inhalations b.i.d.
Number of subjects: 8424
Study 20595145 — intervention group
Group type: COMPARATOR
Intervention: budesonide/formoterol 160/4.5 μg, 1 × 2 inhalations b.i.d.
Number of subjects: 8424
Study 17874255 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (150 or 250 mg)
Number of subjects: 651
Study 17874255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study 16884571 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telecare service
Number of subjects: 653
Study 16884571 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face nurse visiting service
Number of subjects: 653
Study 12791115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg.kg‐1
Number of subjects: 80
Study 12791115 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 30 mg.kg‐1
Number of subjects: 80
Study 12791115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg.kg‐1 plus magnesium sulphate 30 mg.kg‐1
Number of subjects: 80
Study 12791115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10990037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with pre-proliferative/proliferative retinopathy
Number of subjects: 62
Study 10990037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with no retinopathy/background changes
Number of subjects: 62
Study 10990037 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 62
Study 8998681 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin (25 patients)
Number of subjects: 48
Study 8998681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (23 patients)
Number of subjects: 48
Study 8998681 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin plus calcium
Number of subjects: 48
Study 8998681 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus calcium
Number of subjects: 48
Study 1600053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 11
Study 1600053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 60 mg
Number of subjects: 11
Study 1600053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6327141 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 11
Study 6327141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte receptor numbers
Number of subjects: 11
Study 6327141 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline stimulation
Number of subjects: 11
Study 30782680 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (betamethasone) with hyaluronic acid (HA) injection
Number of subjects: 146
Study 30782680 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (betamethasone) injection
Number of subjects: 146
Study 30083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with hearing aids (HAs)
Number of subjects: 42
Study 30083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with normal hearing (NH)
Number of subjects: 42
Study 27577510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (270 mg I/mL iodixanol)
Number of subjects: 90
Study 27577510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (320 mg I/mL iodixanol)
Number of subjects: 90
Study 27577510 — intervention group
Group type: COMPARATOR
Intervention: Group C (320 mg I/mL iodixanol, conventional retrospective ECG gating mode)
Number of subjects: 90
Study 24522334 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (N=296)
Number of subjects: 587
Study 24522334 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch (N=291)
Number of subjects: 587
Study 20964565 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% spironolactone gel
Number of subjects: 78
Study 20964565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 19223621 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 administered at 10 mg/kg/day for 14 days
Number of subjects: 0
Study 19223621 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-246 administered at 3 mg/kg to 100 mg/kg once a day for 14 days
Number of subjects: 0
Study 19223621 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dosage of ST-246 400 mg once daily for 14 days
Number of subjects: 0
Study 17502345 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal/genital cleaning with soap
Number of subjects: 350
Study 17502345 — intervention group
Group type: COMPARATOR
Intervention: No cleaning of the perineum
Number of subjects: 350
Study 15325892 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% C31G
Number of subjects: 61
Study 15325892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% C31G
Number of subjects: 61
Study 15325892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7% C31G
Number of subjects: 61
Study 15325892 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 61
Study 11251703 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 17
Study 11251703 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (trihexyphenidyl)
Number of subjects: 17
Study 9704763 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic gestodene
Number of subjects: 99
Study 9704763 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic gestodene
Number of subjects: 99
Study 9704763 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel
Number of subjects: 99
Study 9704763 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 99
Study 8053615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (8 g twice daily)
Number of subjects: 21
Study 3270328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine infusion (IV)
Number of subjects: 0
Study 3270328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution infusion)
Number of subjects: 0
Study 29730540 — intervention group
Group type: EXPERIMENTAL
Intervention: Target sequence (10 trials)
Number of subjects: 212
Study 29730540 — intervention group
Group type: EXPERIMENTAL
Intervention: Target sequence (10 trials) + distractor sequences (3 trials)
Number of subjects: 212
Study 29730540 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding first-trial data (silent practice trial)
Number of subjects: 212
Study 26619355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 50
Study 26619355 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic placebo cream
Number of subjects: 50
Study 24919692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein supplementation (20.7 g of protein, 9.3 g of carbohydrate, and 3.0 g of fat) twice daily
Number of subjects: 23
Study 24919692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no protein supplementation)
Number of subjects: 23
Study 24919692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PRO and CON)
Number of subjects: 23
Study 24919692 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO group only
Number of subjects: 23
Study 22624502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg every 12 hours for 10 days
Number of subjects: 0
Study 22624502 — intervention group
Group type: COMPARATOR
Intervention: Danoprevir 100 mg alone
Number of subjects: 0
Study 20883290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate (SS)
Number of subjects: 0
Study 18928104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupi Xiaosan Recipe (RPXSR)
Number of subjects: 100
Study 18928104 — intervention group
Group type: COMPARATOR
Intervention: Rukang Tablet (RKT)
Number of subjects: 100
Study 16629762 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon
Number of subjects: 90
Study 16629762 — intervention group
Group type: COMPARATOR
Intervention: Avonex
Number of subjects: 90
Study 16629762 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif
Number of subjects: 90
Study 12747193 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus traditional Chinese medicine (TCM)
Number of subjects: 47
Study 12747193 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 47
Study 10805507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociated diet (food combining)
Number of subjects: 54
Study 10805507 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced diet
Number of subjects: 54
Study 9101956 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D vision system
Number of subjects: 0
Study 9101956 — intervention group
Group type: COMPARATOR
Intervention: 2-D vision system
Number of subjects: 0
Study 1602793 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified LSA2L2 therapy with less intensive intrathecal chemotherapy and no radiotherapy
Number of subjects: 193
Study 1602793 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified LSA2L2 therapy with intensified intrathecal therapy and radiotherapy
Number of subjects: 193
Study 1602793 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐cell 2 therapy
Number of subjects: 193
Study 1602793 — intervention group
Group type: COMPARATOR
Intervention: Modified LSA2L2 therapy (with or without intensified intrathecal chemotherapy and radiotherapy)
Number of subjects: 193
Study 3913377 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute ethanol embolization
Number of subjects: 30
Study 3913377 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam embolization
Number of subjects: 30
Study 30107586 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Me, Healthy We intervention (8-month campaign delivered by child care centers with branded materials)
Number of subjects: 0
Study 29144061 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily
Number of subjects: 462
Study 29144061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 26923491 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily review of antimicrobial use
Number of subjects: 0
Study 25344703 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (6 sessions)
Number of subjects: 40
Study 25344703 — intervention group
Group type: COMPARATOR
Intervention: Recreational group discussion (control)
Number of subjects: 40
Study 22828921 — intervention group
Group type: EXPERIMENTAL
Intervention: G. glauca herbal medicinal product (0.175 mg of galphimine-B, one or two capsules twice a day for 12 weeks plus 3 withdrawal weeks)
Number of subjects: 191
Study 22828921 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (0.5 mg with the same presentation and posology)
Number of subjects: 191
Study 22828921 — intervention group
Group type: EXPERIMENTAL
Intervention: G. glauca herbal medicinal product
Number of subjects: 191
Study 20225073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined posterior lumbar plexus (PLP) and sciatic nerve blocks
Number of subjects: 0
Study 20225073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of femoral, lateral femoral cutaneous, and sciatic nerve blocks with obturator nerve block
Number of subjects: 0
Study 20225073 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous postoperative PLP block
Number of subjects: 0
Study 20225073 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block
Number of subjects: 0
Study 18632241 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily)
Number of subjects: 44
Study 18632241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 18632241 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 44
Study 16802896 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group (n = 133) with intervention including videotaped examples, problem-solving activities, and self-critique through video procedures across 10 home visits.
Number of subjects: 264
Study 16802896 — intervention group
Group type: COMPARATOR
Intervention: Developmental feedback comparison group (n = 131) as control.
Number of subjects: 264
Study 16802896 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group (n = 133) with intervention.
Number of subjects: 264
Study 14669193 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric muscle stimulation (EMS) of the vastus medialis muscle for 4 hours a day, starting on postoperative day 2, over the first 6 postoperative weeks
Number of subjects: 30
Study 14669193 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 30
Study 10949680 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms kg-1)
Number of subjects: 30
Study 10949680 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (100 micrograms kg-1)
Number of subjects: 30
Study 8848991 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 31
Study 8848991 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 31
Study 1375648 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% applied 4 times daily for 4 weeks
Number of subjects: 21
Study 1375648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 4024019 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg
Number of subjects: 12
Study 4024019 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 5 mg/kg
Number of subjects: 12
Study 31912649 — intervention group
Group type: EXPERIMENTAL
Intervention: Early market access to iodized salt
Number of subjects: 1220
Study 31912649 — intervention group
Group type: COMPARATOR
Intervention: Control (later access to iodized salt)
Number of subjects: 1220
Study 29725747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instruments (PSI)
Number of subjects: 163
Study 29725747 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 163
Study 28166129 — intervention group
Group type: EXPERIMENTAL
Intervention: Novice (NOV) group
Number of subjects: 95
Study 28166129 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced (EXP) group
Number of subjects: 95
Study 28166129 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 95
Study 25959877 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane group (n = 32)
Number of subjects: 64
Study 25959877 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane group (n = 32)
Number of subjects: 64
Study 23421857 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program
Number of subjects: 23
Study 23421857 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 23
Study 21617554 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus Ayurvedic placebo (n = 14)
Number of subjects: 43
Study 21617554 — intervention group
Group type: COMPARATOR
Intervention: Ayurveda plus MTX placebo (n = 12)
Number of subjects: 43
Study 21617554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurveda plus MTX (n = 17)
Number of subjects: 43
Study 21617554 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in MTX group
Number of subjects: 43
Study 21617554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in Ayurveda group
Number of subjects: 43
Study 21617554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in combination group
Number of subjects: 43
Study 18422727 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg p277
Number of subjects: 48
Study 18422727 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg p277
Number of subjects: 48
Study 18422727 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg p277
Number of subjects: 48
Study 18422727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16543910 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine 1-2 mg/day
Number of subjects: 37
Study 16543910 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50-100 mg/day
Number of subjects: 37
Study 15017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors)
Number of subjects: 0
Study 15017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 0
Study 15017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antihypertensive therapy including ACE inhibitors or ARBs
Number of subjects: 0
Study 15017529 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 15017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 11195999 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 53
Study 11195999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9322717 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline lavage
Number of subjects: 152
Study 9322717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic or antibiotic lavage
Number of subjects: 152
Study 9322717 — intervention group
Group type: COMPARATOR
Intervention: No saline lavage (control group)
Number of subjects: 152
Study 8258115 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural morphine
Number of subjects: 22
Study 8258115 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural morphine
Number of subjects: 22
Study 3888367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen (prochlorperazine, dexamethasone, pentobarbital)
Number of subjects: 27
Study 3888367 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 27
Study 30915573 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-DWI in abscess group
Number of subjects: 19
Study 30915573 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine postoperative MRI-DWI)
Number of subjects: 19
Study 29533303 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir‐emtricitabine plus atazanavir/ritonavir
Number of subjects: 234
Study 29533303 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir‐emtricitabine plus darunavir/ritonavir
Number of subjects: 234
Study 29533303 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir‐emtricitabine plus raltegravir
Number of subjects: 234
Study 29533303 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma OPG levels at week 48 and 96
Number of subjects: 234
Study 29533303 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma RANKL and RANKL/OPG ratio levels
Number of subjects: 234
Study 27687537 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss + 2000IU oral vitamin D3/day
Number of subjects: 100
Study 27687537 — intervention group
Group type: COMPARATOR
Intervention: Weight loss + daily placebo
Number of subjects: 100
Study 25252818 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in skirt size (CSS) per 10 years
Number of subjects: 92834
Study 25252818 — intervention group
Group type: EXPERIMENTAL
Intervention: Current skirt size at study entry
Number of subjects: 92834
Study 25252818 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at recruitment
Number of subjects: 92834
Study 25252818 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in skirt size (CSS) and BMI in the model
Number of subjects: 92834
Study 22404114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-atracurium (CIS) 0.15 mg/kg
Number of subjects: 65
Study 22404114 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (SUC) 1 mg/kg
Number of subjects: 65
Study 20471549 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over the hand area of the M1 for 20 minutes at 1mA for five consecutive days.
Number of subjects: 21
Study 20471549 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS applied over the hand area of the M1 for 20 minutes at 1mA for five consecutive days.
Number of subjects: 21
Study 16880195 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural graded activity (97 patients)
Number of subjects: 200
Study 16880195 — intervention group
Group type: COMPARATOR
Intervention: Usual care (103 patients)
Number of subjects: 200
Study 16880195 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural graded activity
Number of subjects: 200
Study 16880195 — intervention group
Group type: COMPARATOR
Intervention: Behavioural graded activity vs Usual care
Number of subjects: 200
Study 15661840 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise with local heating at 41 degrees C
Number of subjects: 0